Abstract
The goal of this study was to determine if serotonergic activity, which is impaired in depression, regulates the phosphorylation of glycogen synthase kinase-3β (GSK3β) in mouse brain in vivo. GSK3β is inhibited by phosphorylation on serine-9 and is a target of the mood stabilizer lithium. Following administration to mice of d-fenfluramine to stimulate serotonin (5HT) release and reduce its reuptake, and clorgyline to inhibit 5HT catabolism, levels of phospho-Ser9-GSK3β were 300–400% of control levels in the prefrontal cortex, hippocampus, and striatum. Treatment with monoamine reuptake inhibitors fluoxetine and imipramine also increased the level of phospho-Ser9-GSK3β. Using receptor selective agonists and antagonists, 5HT1A receptors were found to mediate increases, and 5HT2 receptors decreases, in phospho-Ser9-GSK3β levels. This indicates that serotonergic regulation of the phosphorylation of GSK3β is achieved by a balance between the opposing actions of these 5HT receptor subtypes. These findings demonstrate for the first time that serotonergic activity regulates the phosphorylation of GSK3β and show that this regulation occurs in mammalian brain in vivo. These results raise the possibility that impaired inhibitory control of GSK3β may occur in conditions where serotonergic activity is dysregulated, such as in mood disorders.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72: 248–254.
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785–789.
De Sarno P, Li X, Jope RS (2002). Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158–1164.
Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ et al (1999). PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46: 1375–1387.
Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597–606.
Fang X, Yu SX, Lu Y, Bast Jr RC, Woodgett JR, Mills GB (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 97: 11960–11965.
Frame S, Cohen P (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1–16.
Goode N, Hughes K, Woodgett JR, Parker PJ (1992). Differential regulation of glycogen synthase kinase-3β by protein kinase C isotypes. J Biol Chem 267: 16878–16882.
Grimes CA, Jope RS (2001). The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol 65: 391–426.
Hsiung SC, Adlersberg M, Arango V, Mann JJ, Tamir H, Liu KP (2003). Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. J Neurochem 87: 182–194.
Ichimiya T, Suhara T, Sudo Y, Okubo Y, Nakayama K, Nankai M et al (2002). Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatry 51: 715–722.
Jope RS (2003). Lithium and GSK3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24: 441–443.
Jope RS, Johnson VWJ (2004). The glamour and gloom glycogen synthase kinase-3. Trends Biochem Sci 29: 95–102.
Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455–8459.
Lesort M, Greendorfer A, Stockmeier C, Johnson GVW, Jope RS (1999). Glycogen synthase kinase-3β, β-catenin, and tau in postmortem bipolar brain. J Neural Transm 106: 1217–1222.
Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA (2000). Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3β. Mol Cell Biol 20: 9356–9363.
Middlemiss DN, Price GW, Watson JM (2002). Serotonergic targets in depression. Curr Opin Pharmacol 2: 18–22.
Owens MJ, Nemeroff CB (1994). Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40: 288–295.
Phiel CJ, Klein PS (2001). Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789–813.
Rajkowska G (2002). Cell pathology in mood disorders. Semin Clin Neuropsychiatry 7: 281–292.
Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J et al (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174–180.
Stockmeier CA (2003). Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res 37: 357–373.
Yatham LN, Steiner M (1993). Neuroendocrine probes of serotonergic function: a critical review. Life Sci 53: 447–463.
Acknowledgements
This research was supported by National Institutes of Health grants MH67712 (XL) and MH38752 (RSJ).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, X., Zhu, W., Roh, MS. et al. In Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain. Neuropsychopharmacol 29, 1426–1431 (2004). https://doi.org/10.1038/sj.npp.1300439
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300439
Keywords
This article is cited by
-
The role of serotonin neurotransmission in rapid antidepressant actions
Psychopharmacology (2022)
-
Triiodothyronine Treatment reverses Depression-Like Behavior in a triple-transgenic animal model of Alzheimer’s Disease
Metabolic Brain Disease (2022)
-
Neonatal Reserpine Administration Produces Widespread Neuronal Losses and ⍺-Synuclein Inclusions in a Rat Model
Neurotoxicity Research (2021)
-
Lithium chloride enhances serotonin induced calcium activity in EGFP-GnIH neurons
Scientific Reports (2020)
-
Prediction of lithium treatment response in bipolar depression using 5-HTT and 5-HT1A PET
European Journal of Nuclear Medicine and Molecular Imaging (2020)
